This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Medical Crossfire<sup>®</sup>: Navigating the PCSK9 Inhibitor Frontier: A Guide to Understanding the Clinical Implications of Recent PCSK9 Inhibitor Trials

Medical Crossfire®: Navigating the PCSK9 Inhibitor Frontier: A Guide to Understanding the Clinical Implications of Recent PCSK9 Inhibitor Trials

Format

Roundtable

Time to Complete

1 hour

Released

December 28, 2017

Expires

December 28, 2018
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider

Jointly provided by Global Education Group and Physicians' Education Resource®, LLC (PER®)

Commercial Supporter

Supported by an educational grant from Amgen Inc.

Program Description

This crossfire is designed to educate clinicians regarding the latest clinical trial evidence for PCSK9 inhibitors (PCSK9i), emphasizing results from studies that evaluated coronary risk and cardiovascular outcomes. They will discuss the efficacy and safety data supporting these therapies, and the role of new therapies alongside traditional dyslipidemia treatment options. The activity will go beyond a simple overview of the trial results to guide clinicians in how to interpret the clinical implications of the findings to improve the management of CV risk in their patients.

Intended Audience

This educational activity is directed toward lipidologists, cardiologists, nurse practitioners, nurses, physician assistants, researchers, and other healthcare professionals interested in the treatment of hypercholesterolemia.

Educational Objectives

At the conclusion of this activity, participants should be better able to:

  • Determine optimal LDL-C target goals in high-risk individuals in light of current consensus recommendations
  • Review the latest clinical trial data for the novel LDL-C lowering agents, PCSK9 inhibitors, and their potential application to address ASCVD risk in clinical practice
  • Discuss new data and how it will benefit individualized treatment plans to improve outcomes and lower the risk of cardiovascular events for patients with dyslipidemia

Disclosure of Conflicts of Interest Policy

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Faculty

Elliot A. Brinton, MD, FAHA, FNLA
President, Utah Lipid Center
Salt Lake City, UT

Dr. Brinton discloses the following:
Consultant: Amgen, Kowa, Regeneron, and Sanofi
Speakers Bureau: Amgen, Kowa, Regeneron, and Sanofi

Michael Davidson, MD, FACC, FNLA
Professor at the University of Chicago Pritzker School of Medicine
Chicago, IL

Dr. Davidson discloses the following:
Consultant: Amgen, AstraZeneca, Merck, Novo Nordisk, Regeneron, and Sanofi US
Speakers Bureau: Amgen, Novo Nordisk, Regeneron, and Sanofi US


Peter Salgo, MD
Professor of Medicine and Anesthesiology
Columbia University College of Physicians and Surgeons
New York, NY

Dr. Salgo has no relevant financial relationships with commercial interests to disclose.

James Underberg, MD
President of the National Lipid Association
Clinical Assistant Professor of Medicine at the New York University School of Medicine
New York, NY

Dr. Underberg discloses the following:
Grant Research Support: Aegerion and Pfizer
Consultant: Amarin and Amgen
Speakers Bureau: Alexioin, Amarin, Amgen, Kowa, Regeneron, Sanofi, and True Health Diagnostics

Accredited Provider Disclosure

Global Education Group
Planning StaffLindsay Borvansky; Andrea Funk; and Liddy Knight have no relevant financial relationships with commercial interests to disclose.

Publishing Staff Disclosures

Physicians' Education Resource®, LLC (PER®)
Planning StaffDavid Heckard; Maryjo Dixon, RPh; Neelam Davis, PharmD; and Kathleen Bowen have no relevant financial relationships with commercial interests to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Physicians’ Education Resource®, LLC (PER®). Global is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Global Education Group designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue